Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FA2Z3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,163
Award facts
- Contract value 100% obligated
- $25,163.01 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 20, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $25,163.01 to AmerisourceBergen Drug Corp for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, with an ultimate completion date of January 21, 2026, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc.'s, larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award IDC valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
Cencora, Inc. (doing business as AmerisourceBergen) is a major pharmaceutical distributor and healthcare solutions provider that supplies a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to federal agencies, particularly the Department of Defense and Department of Veterans Affairs. Cosentyx is a biologic immunosuppressant used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, making it consistent with the contractor's established portfolio of specialty medications supplied to military treatment facilities and veterans' healthcare programs.
Quick answers
Who was awarded contract SPE2DR26FA2Z3?
SPE2DR26FA2Z3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FA2Z3 worth?
The government has obligated $25,163 on SPE2DR26FA2Z3.
Is contract SPE2DR26FA2Z3 an order under another contract?
Yes. SPE2DR26FA2Z3 is a delivery order under SPE2DR25D2014, an indefinite delivery contract.
Was contract SPE2DR26FA2Z3 competed?
The extent of competition for SPE2DR26FA2Z3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award